Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
/in Breast Cancer, Dendritic Cells, International Publications /von 2004-02-25 / Cancer Immunol Immunother 2004 Jul;53(7):633-41Dendritic cell-based therapeutics for breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2004-01-01 / Breast Dis 2004;20:65-71The immune response to breast cancer, and the case for DC immunotherapy
/in Breast Cancer, Dendritic Cells, International Publications /von 2004-01-01 / Cytotherapy 2004;6(2):154-63Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-10-01 / Clin. Cancer Res. 2003 Oct;9(12):4376-86Dendritic cell-based vaccines in breast and gynaecologic cancer
/in Breast Cancer, Cervical Cancer, Dendritic Cells, International Publications, Ovarian Cancer /von 2003-09-01 / Anticancer Res. 2003 Sep-Oct;23(5b):4293-303In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-06-15 / J. Surg. Res. 2003 Jun;112(2):189-97The effect of whole-body hyperthermia combined with ‚metronomic‘ chemotherapy on rat mammary adenocarcinoma metastases
/in Breast Cancer, Hyperthermia, International Publications /von 2003-03-01 / Int J Hyperthermia 2003 Mar-Apr;19(2):103-18Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-02-15 / J. Immunol. 2003 Feb;170(4):1980-6Fusions of breast cancer and dendritic cells as a novel cancer vaccine
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-02-01 / Clin. Breast Cancer 2003 Feb;3 Suppl 4:S158-63
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de